stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Return on assets
Sanofi's return on assets over the twelve months to 30 September 2026 was 3.24%, down 2.9 percentage points from fiscal 2025 (6.16%). Over the past ten years it has ranged from 2.44% (fiscal 2019) to 10.9% (fiscal 2020); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 6.16% | 1.87 |
| FY2024 | 4.29% | (0.03) |
| FY2023 | 4.32% | (2.08) |
| FY2022 | 6.40% | 1.01 |
| FY2021 | 5.39% | (5.55) |
| FY2020 | 10.9% | 8.50 |
| FY2019 | 2.44% | (1.72) |
| FY2018 | 4.16% | (4.18) |
| FY2017 | 8.34% | 3.80 |
| FY2016 | 4.54% | 0.62 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| AMGN Amgen Inc. compare | 10.1% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| AZN AstraZeneca PLC compare | 9.41% |
| NVS Novartis AG compare | 8.94% |
| GSK GSK PLC Sponsored ADR compare | 6.53% |
| SNY Sanofi | 3.24% |
| PFE Pfizer Inc. compare | 1.95% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement